CNBX Pharmaceuticals Inc. (CNBX) Capital Expenditures (2014 - 2023)

CNBX Pharmaceuticals' (CNBX) quarterly Capital Expenditures came in at $1196.0 in Q4 2023, up 4.64% on a QoQ basis from $1143.0 in Q3 2022.

CNBX Pharmaceuticals Inc. (CNBX) Capital Expenditures (2014 - 2023) Analysis & Trends

CNBX Pharmaceuticals (CNBX) has 9 years of Capital Expenditures data on file, last reported at $1196.0 in Q4 2023.

Quarterly Capital Expenditures changed N/A year-over-year to $1196.0 in Q4 2023, while the trailing twelve-month figure through Aug 2024 was $1196.0 (changed N/A YoY) and the FY2024 annual result came in at $1196.0, changed N/A from the prior year.
Capital Expenditures improved to $1196.0 in Q4 2023, from $1143.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $72361.0 in Q2 2019 to a low of $26.0 in Q3 2020.
A 5-year average of $20004.5 and a median of $5100.0 in 2020 frame the typical range for Capital Expenditures.
The widest YoY moves for Capital Expenditures: up 15.95% in 2020, down 99.91% in 2020.
Tracing CNBX's Capital Expenditures over 5 years: stood at $9800.0 in 2019, then slumped by 90.38% to $943.0 in 2020, then slumped by 45.6% to $513.0 in 2021, then surged by 122.81% to $1143.0 in 2022, then gained by 4.64% to $1196.0 in 2023.
The last three Capital Expenditures figures came in at $1196.0 (Q4 2023), $1143.0 (Q3 2022), and $513.0 (Q4 2021), per Business Quant data.

Download Data